Recombinant Human IL-36β, 153a.a. (Recombinant Human Interleukin-36β, 153a.a.; rHuIL-36β, 153a.a.);重组人白细胞介素36β,153a.a.
Synonyms
IL36B; IL1F8; IL1H2
Purity
>97% by SDS-PAGE and HPLC analyses.
Biological Activity
Fully biologically active when compared to standard. The ED50 as determined by inducing IL-8 secretion in human preadipocytes is less than 10ng/ml, corresponding to a specific activity of >1.0×105IU/mg.
Physical Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation
Lyophilized from a 0.2μm filtered concentrated solution in 2X PBS, pH7.4.
Endotoxin
Less than 1EU/μg of rHuIL-36β, 153a.a. as determined by LAL method.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤-20℃. Further dilutions should be made in appropriate buffered solutions.
Category
Cytokine
Background
Interleukin-36 (IL-36) is a pro-inflammatory cytokine which plays an important role in the pathophysiology of several diseases. IL-36α, IL-36β, and IL-36γ (formerly IL-1F6, IL-1F8, and IL-1F9) are IL-1 family members that signal through the IL-1 receptor family members IL-1Rrp2 (IL-1RL2) and IL-1RAcP. IL-36 beta is reported to be expressed at higher levels in psoriatic plaques than in symptomless psoriatic skin or healthy control skin and it can stimulate production of interleukin-6 and interleukin-8 in synovial fibrobasts, articular chondrocytes and mature adipocytes. It has two isoforms. IL-36β isoform 2 contains one potential N-linked glycosylation site in its C-terminus, while IL-36β isoform 1 lacks potential N-linked glycosylation sites and four of the conserved β-strands. Human IL-36β isoform 2 shares 62%, 67%, 63% and 59%a.a. identity with the most similar isoform of mouse, canine, bovine and equine IL-36β, respectively.